South Korea · Delayed Price · Currency is KRW SK bioscience Statistics
Total Valuation
SK bioscience has a market cap or net worth of KRW 2.96 trillion. The enterprise value is 2.93 trillion.
| Market Cap | 2.96T |
| Enterprise Value | 2.93T |
Important Dates
The next estimated earnings date is Friday, October 23, 2026.
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SK bioscience has 78.04 million shares outstanding. The number of shares has increased by 0.59% in one year.
| Current Share Class | 78.04M |
| Shares Outstanding | 78.04M |
| Shares Change (YoY) | +0.59% |
| Shares Change (QoQ) | -0.50% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 2.44% |
| Float | 25.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.49 |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 662.12 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.27.
| Current Ratio | 3.60 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.03 |
| Interest Coverage | -10.36 |
Financial Efficiency
Return on equity (ROE) is -4.25% and return on invested capital (ROIC) is -7.75%.
| Return on Equity (ROE) | -4.25% |
| Return on Assets (ROA) | -2.81% |
| Return on Invested Capital (ROIC) | -7.75% |
| Return on Capital Employed (ROCE) | -4.96% |
| Weighted Average Cost of Capital (WACC) | 7.86% |
| Revenue Per Employee | 718.94M |
| Profits Per Employee | -92.36M |
| Employee Count | 917 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 2.73 |
Taxes
| Income Tax | -15.60B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.89% in the last 52 weeks. The beta is 0.86, so SK bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -22.89% |
| 50-Day Moving Average | 36,242.00 |
| 200-Day Moving Average | 43,667.00 |
| Relative Strength Index (RSI) | 54.13 |
| Average Volume (20 Days) | 83,613 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SK bioscience had revenue of KRW 659.27 billion and -84.70 billion in losses. Loss per share was -1,080.54.
| Revenue | 659.27B |
| Gross Profit | 93.53B |
| Operating Income | -131.25B |
| Pretax Income | -101.18B |
| Net Income | -84.70B |
| EBITDA | -33.04B |
| EBIT | -131.25B |
| Loss Per Share | -1,080.54 |
Balance Sheet
The company has 832.60 billion in cash and 543.37 billion in debt, with a net cash position of 289.24 billion or 3,706.28 per share.
| Cash & Cash Equivalents | 832.60B |
| Total Debt | 543.37B |
| Net Cash | 289.24B |
| Net Cash Per Share | 3,706.28 |
| Equity (Book Value) | 2.01T |
| Book Value Per Share | 22,354.26 |
| Working Capital | 868.66B |
Cash Flow
In the last 12 months, operating cash flow was 4.47 billion and capital expenditures -139.22 billion, giving a free cash flow of -134.75 billion.
| Operating Cash Flow | 4.47B |
| Capital Expenditures | -139.22B |
| Depreciation & Amortization | 98.21B |
| Net Borrowing | 101.33B |
| Free Cash Flow | -134.75B |
| FCF Per Share | -1,726.67 |
Margins
Gross margin is 14.19%, with operating and profit margins of -19.91% and -12.85%.
| Gross Margin | 14.19% |
| Operating Margin | -19.91% |
| Pretax Margin | -15.35% |
| Profit Margin | -12.85% |
| EBITDA Margin | -5.01% |
| EBIT Margin | -19.91% |
| FCF Margin | n/a |
Dividends & Yields
SK bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.59% |
| Shareholder Yield | -0.59% |
| Earnings Yield | -2.86% |
| FCF Yield | -4.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for SK bioscience is 32,500.00, which is -14.25% lower than the current price. The consensus rating is "Sell".
| Price Target | 32,500.00 |
| Price Target Difference | -14.25% |
| Analyst Consensus | Sell |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 9.31% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SK bioscience has an Altman Z-Score of 2.87 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.87 |
| Piotroski F-Score | 4 |